IL-33 increases ST2⁺ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner

References

• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3): 1151–1164.
   PubMed Web of Science ®Google Scholar
• Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Reviews Immunol. 2007;7(11):875–888. doi:10.1038/nri2189.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Ph K. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.
   PubMed Web of Science ®Google Scholar
• Halvorsen EC, Mahmoud SM, Kl B. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev. 2014;33(4):1025–1041. doi:10.1007/s10555-014-9529-x.
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Ek V. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep. 2016;6:39247.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Ah B. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2006;24(34):5373–5380. doi:10.1200/JCO.2006.05.9584.
   PubMed Web of Science ®Google Scholar
• Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–553. doi:10.1038/nature09707.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904. doi:10.1038/nm1469.
   PubMed Web of Science ®Google Scholar
• Halvorsen EC, Hamilton MJ, Young A, Wadsworth BJ, LePard NE, Lee HN, Firmino N, Collier JL, Kl B. Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology. 2016;5(6):e1150398. doi:10.1080/2162402X.2016.1150398.
   PubMed Web of Science ®Google Scholar
• Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Rf W. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (80-). 2005;309(5739):1380–1384. doi:10.1126/science.1113401.
   PubMed Web of Science ®Google Scholar
• Bos PD, Plitas G, Rudra D, Lee SY, Ay R. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med. 2013;210(11):2435–2466. doi:10.1084/jem.20130762.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, Treuting PM, Ay R. A distinct function of regulatory t cells in tissue protection. Cell. 2015;162(5):1078–1089. doi:10.1016/j.cell.2015.08.021.
   PubMed Web of Science ®Google Scholar
• Christianson CA, Goplen NP, Zafar I, Irvin C, Good JT Jr., Rollins DR, Gorentla B, Liu W, Gorska MM, Chu H, et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J Allergy Clin Immunol. 2015;136(1):59–68. e14. doi:10.1016/j.jaci.2014.11.037.
   PubMed Web of Science ®Google Scholar
• Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, Graham GJ, Kurowska-Stolarska M, Liew FY, McSharry C, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol. 2014;134(6):1422–1432. e1411. doi:10.1016/j.jaci.2014.05.011.
   PubMed Web of Science ®Google Scholar
• Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC, Wagers AJ, Benoist C, Mathis D. Poor Repair of Skeletal Muscle in Aging Mice Reflects a Defect in Local, Interleukin-33-Dependent Accumulation of Regulatory T Cells. Immunity. 2016;44(2):355–367. doi:10.1016/j.immuni.2016.01.009.
   PubMed Web of Science ®Google Scholar
• Cayrol C, Jp G. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31::31–37. doi:10.1016/j.coi.2014.09.004.
   PubMed Web of Science ®Google Scholar
• Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint, Bone, Spine: Revue Du Rhumatisme. 2012;79(1):32–37. doi:10.1016/j.jbspin.2011.02.011.
   PubMed Web of Science ®Google Scholar
• Liew FY, Girard JP, Hr T. Interleukin-33 in health and disease. Nat Reviews Immunol. 2016;16(11):676–689. doi:10.1038/nri.2016.95.
   PubMed Web of Science ®Google Scholar
• Kakkar R, Rt L. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discovery. 2008;7(10):827–840. doi:10.1038/nrd2660.
   PubMed Web of Science ®Google Scholar
• Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol. 2015;16(3):276–285. doi:10.1038/ni.3085.
   PubMed Web of Science ®Google Scholar
• Griesenauer B. Paczesny S: the ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.
   PubMed Web of Science ®Google Scholar
• Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci U S A. 2015;112(34):10762–10767. doi:10.1073/pnas.1509070112.
   PubMed Web of Science ®Google Scholar
• Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, Angelosanto JM, Laidlaw BJ, Yang CY, Sathaliyawala T, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045–1054. doi:10.1031/ni.2131.
   PubMed Web of Science ®Google Scholar
• Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119–131. doi:10.1016/j.bbcan.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Zaiss DM, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42(2):216–226. doi:10.1016/j.immuni.2015.01.020.
   PubMed Web of Science ®Google Scholar
• Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, Sefik E, Tan TG, Wagers AJ, Benoist C, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155(6):1282–1295. doi:10.1016/j.cell.2013.10.054.
   PubMed Web of Science ®Google Scholar
• Kariagina A, Xie J, Leipprandt JR, Sz H. Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer. 2010;1(5):229–244. doi:10.1007/s12672-010-0048-0.
   PubMedGoogle Scholar
• Ma L, de Roquancourt A, Bertheau P, Chevret S, Millot G, Sastre-Garau X, Espie M, Marty M, Janin A, Calvo F. Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions. J Pathol. 2001;194(4): 413–419.
   PubMed Web of Science ®Google Scholar
• Green JA, Arpaia N, Schizas M, Dobrin A, Ay R. A nonimmune function of T cells in promoting lung tumor progression. J Exp Med. 2017;214(12):3565–3575. doi:10.1084/jem.20170356.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Bosiljcic M, Lepard NE, Halvorsen EC, Ho VW, Banath JP, Krystal G, Kl B. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. J Immunol. 2014;192(1):512–522. doi:10.4049/jimmunol.1300096.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Halvorsen EC, LePard NE, Bosiljcic M, Ho VW, Lam V, Banath J, Bennewith KL, Krystal G. SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice. Oncotarget. 2016;7(4):3677–3691. doi:10.18632/oncotarget.6611.
   PubMedGoogle Scholar
• Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, McKenzie AN, Takei F. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425–435. doi:10.1016/j.immuni.2014.01.011.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez I, Matha L, Steer CA, Ghaedi M, Poon GF, Takei F. Allergen-experienced group 2 innate lymphoid cells acquire memory-like properties and enhance allergic lung inflammation. Immunity. 2016;45(1):198–208. doi:10.1016/j.immuni.2016.06.017.
   PubMed Web of Science ®Google Scholar
• Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, He V. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006;20(11):1496–1510. doi:10.1101/gad.1417406.
   PubMed Web of Science ®Google Scholar
• Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs. 2014;74(2):207–221. doi:10.1007/s40265-013-0170-8.
   PubMed Web of Science ®Google Scholar
• Tanaka A. Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118. doi:10.1038/cr.2016.151.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226–230. doi:10.1038/nature10169.
   PubMed Web of Science ®Google Scholar
• Moussion C, Ortega N, Jp G. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS One. 2008;3(10):e3331. doi:10.1371/journal.pone.0003331.
   PubMed Web of Science ®Google Scholar
• Martin NT, Mu M. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016;17(2):122–131. doi:10.1038/ni.3370.
   PubMed Web of Science ®Google Scholar
• Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84–98. doi:10.1016/j.immuni.2009.05.007.
   PubMed Web of Science ®Google Scholar
• Heppner GH, Miller FR, Pm S. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2(5): 331–334.
   PubMed Web of Science ®Google Scholar
• Siede J, Frohlich A, Datsi A, Hegazy AN, Varga DV, Holecska V, Saito H, Nakae S, Lohning M. IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell Proliferation through IL-10 and TGFbeta Release. PLoS One. 2016;11(8):e0161507. doi:10.1371/journal.pone.0161507.
   PubMed Web of Science ®Google Scholar
• Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, Hr T. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol. 2014;193(8):4010–4020. doi:10.4049/jimmunol.1400481.
   PubMed Web of Science ®Google Scholar
• Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Ml L. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134(7):1669–1682. doi:10.1002/ijc.28481.
   PubMed Web of Science ®Google Scholar
• Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, Jonjic S, Ml L. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 2011;41(7):1902–1912. doi:10.1002/eji.201141417.
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Sw S. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2008;13(2):181–194. doi:10.1007/s10911-008-9084-6.
   PubMed Web of Science ®Google Scholar
• Hurbin A, Dubrez L, Coll JL, Favrot MC. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. Ann N Y Acad Sci. 2003;1010:354–357.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, Ding Q, Xia J. Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EGFR/GSK-3beta/Foxp3 Axis. J Biol Chem. 2016;291(40):21085–21095. doi:10.1074/jbc.M116.717892.
   PubMed Web of Science ®Google Scholar
• Cn J, Ye S, Cao Y, Ad B, Rs C, Ling X, Rp R, Jp D, Bl E, Al N, et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech. 2015;8(3):237–251. doi:10.1242/dmm.017830.
   PubMed Web of Science ®Google Scholar